BII Creation House (Incubation) Program

Application opens
2019, 12pm (CET)
Award amount:
Up to DKK 34 mio. available for granting
Announcement of results:
May 2019


BioInnovation Institute (BII) will promote collaborative, interdisciplinary, research-based innovation in the life sciences and help build viable start-up companies with the necessary skills to ensure such innovations become widely available solutions for the benefit of human welfare and society.

The BII Incubation Program issues convertible loans for risk free maturation of novel start-up companies within biomedicine, medical technology and biotechnology for both industrial and nutritional applications. Objective is to accelerate early stage technical and commercial validation and increase the scientific maturity of the start-up in order to attract funding that can bring new solutions and innovative products to the market.

The BII Incubation Program is executed on site at the Institute’s incubator, which is located at COBIS in Copenhagen. It is expected that loan recipients relocate to the incubator where open offices and laboratories are offered at a reasonable cost. Here, the companies must carry out their main activities and take active part in the peer-to-peer and social activities.

Success for life sciences companies that complete the BII Incubation Program is attraction of external funding for further development through agreements with investors, venture capital, corporate investments, trade sale or revenue.

Areas of support

Support is provided for Danish anchored life science start-ups, build on a scientific idea/technology that has obtained technical Proof of Concept, to accelerate development of new products or services with a commercial potential within biomedicine, medical technology and biotechnology for both industrial and nutritional projects.

Non-scientific aspects, identified in the business plan, are equally supported by the BII Incubation Program’s convertible loans, e.g. fulfilling regulatory requirements or educational needs.


  • Applying companies for the BII Incubation Program must be represented by one or more individuals with an academic background at master’s level or equivalent.
  • Established companies (CVR registered in Denmark) can submit a convertible loan application for the BII Incubation Program.
  • Company founders from Nordic countries are accepted.
  • Applying companies must have obtained technical proof of concept, have a solid initial business plan and potentially validated partner interest for rapid commercialization.
  • Applying companies must own or have full license to the IPR of their discovery and freedom-to-operate.

Simultaneous applications for BII’s program Proof of Concept and Incubation are not accepted.

Only one application per company is permitted for submission.

If a company submits the same (or a very similar) application in two consecutive application rounds without being granted funding, the company will be quarantined from applying for Incubation convertible loan for the next round, unless the company can show clear project progression.

Companies which have received investments are disqualified from applying for convertible loans (soft and non-dilutive funding are accepted).

Eligibility also implies willingness and ability to relocate physically to the BII Incubator in Copenhagen where laboratories and open offices are provided.


Funding as convertible loans can be issued by up to DKK 10 million paid in tranches over a period of maximum 18 months based on a detailed business plan and budget (including quotes).

Participation in the BII Incubation Program is supported by convertible loans, i.e. loans that are issued unsecured, leaving the companies free from repayment in case their company fail to succeed.

If the company is unable to generate a return, the loan will be converted into a donation (see ”Information and Guidelines for Applicants” for more detailed information on the convertible loans).

The BII Incubation Program’s convertible loans are limited to cover expenses for activities such as:

  • Salary for staff
  • Research activities, e.g. testing and experiments
  • Development of MVP, prototypes
  • Publications
  • Patent applications
  • Commercialization costs, i.e. market analysis

Application process

The application should be completed and submitted using the electronic application system, which can be accessed from this link:

Be aware that you must register as an ‘organisation’ to apply for this call. You must allow two work days for registration of a new company in the system.

The BII Incubator Program application of max. 10,000 characters and a slide-deck of max. 20 slides must cover but is not limited to the following areas:

  • Overview of the project team and their scientific and commercial competencies
  • Demonstration of scientific excellence of research
  • Demonstration of commercial partner interest
  • Business plan, including an overview of scientific/commercial milestones
  • A draft vision for the company following the BII Incubation Program, i.e. what kind of external funding and additional maturity activities are expected for post incubation growth of the company

In addition to the application, we ask for a budget submission in the system.

It is important that applicants carefully read ”Information and Guidelines for Applicants”, before initiating the application process, as this document contains the complete call as well as detailed instructions for the application process.

Evaluation Procedure

The BioInnovation Institute’s selection committee will evaluate the applications and base their assessment and recommendation on the following criteria.

  • The qualifications of the applying project team and their commitment and ability to further progress the project
  • Significance and originality of the idea
  • Commercial potential (e.g. impact, time to market)
  • The IPR and legal situation for the research findings behind the project
  • The suggested approach for further development

The call for the BII Incubation Program follows the below schedule:

Calls open: December 7, 2018
Call close: February 14, 2019, 12 noon
Notification: May 2019

Hervør Lykke Olsen
Scientific Advisor
+45 40207754

By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.